Tounjian Advisory Partners’s Royalty Pharma RPRX Stock Holding History

Tounjian Advisory Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55	Buy	+1	New	+$52	﹤0.01%	765

Other funds holding RPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

NSCM

New South Capital Management Memphis, Tennessee $2.28B AUM 47.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking Tokyo, Japan $45.7B AUM 34.08% 1-Year Est. Return

Tounjian Advisory Partners's RPRX Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Royalty Pharma (RPRX) in Q2 2026: 1 share worth $55. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings.

327 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Tounjian Advisory Partners held 1 share of Royalty Pharma worth $55 as of Q2 2026.
Royalty Pharma was a new Tounjian Advisory Partners position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #765 holding.
327 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.